Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of D2 dopamine receptor gene in prolactin-secreting pituitary adenomas.

Expert opinion on drug metabolism & toxicology - 1 Jan 2010

Filopanti M, Lania A G, Spada A

Abstract excerpt

IMPORTANCE OF THE FIELD: Dopamine-agonists are the treatment of choice of prolactin-secreting pituitary adenomas (PRL-omas). Their actions on D2 dopamine receptor (DRD2) and the clinical outcome may be affected by polymorphisms. AREAS COVERED IN THIS REVIEW: PRL-omas are well-differentiated endoc...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Pharmacogenetics
Share to Polymorphism, Genetic
Share to Dopamine Agonists

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DRD2 gene

Share to PRL gene

Share to Genetic Variation

Share to Receptors, Dopamine D2

Source

Identifiers

PMID: 19929252
DOI: 10.1517/17425250903352501

Genes

DRD2
PRL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19929252-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of D2 dopamine receptor gene in prolactin-secreting pituitary adenomas.PMID 19929252Read ↗

Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas.Semantic proximity Read ↗

Cabergoline and prolactinomas: lack of association between DRD2 polymorphisms and response to treatment.Semantic proximity Read ↗

Does DRD2 polymorphism influence the clinical characteristics of prolactinoma?Semantic proximity Read ↗

A Genetic Assessment of Dopamine Agonist-Induced Impulse Control Disorder in Patients With ProlactinomaSemantic proximity Read ↗

Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents.Semantic proximity Read ↗

Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomasSemantic proximity Read ↗

Dopamine Agonists for the Treatment of Pituitary Tumors: From Ergot Extracts to Next Generation TherapiesSemantic proximity Read ↗

The Correlation between Dopamine Receptor D2 and Catechol-O-Methlytransferase Gene Polymorphisms, Hypothalamic-Pituitary-Thyroid and Hypothalamic-Pituitary-Gonadal Axes Functions, and Antipsychotic Drug-Induced MacroprolactinemiaSemantic proximity Read ↗

Impact of Pharmacogenetic Markers of CYP2D6 and DRD2 on Prolactin Response in Risperidone-Treated Thai Children and Adolescents With Autism Spectrum Disorders.Semantic proximity Read ↗

Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.Semantic proximity Read ↗

Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele.Semantic proximity Read ↗

The dopamine receptor D2 genotype is associated with hyperprolactinemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.